Myeloma clinical case scenarios
PURPOSE OF PROGRAMME:
Analysis and interpretation of recurrent abnormalities associated with myeloma: online interphase FISH analysis with supplementary tests as applicable, and/or fixed cell suspensions for interphase FISH, or DNA for array or NGS studies.
|FISH images online||Qualitative detection of absence/presence of abnormality using FISH or array.|
|Fixed cell suspension for FISH testing (various probes) extracted from Myeloma samples||Qualitative detection of absence/presence of abnormality using FISH or array.|
MATERIAL PROVIDED: Cells: fixed suspension, DNA in TE buffer, Images: FISH (Fluorescent In-situ Hybridisation), Images: G-banded chromosomes
DISTRIBUTIONS PER YEAR: 1
SAMPLES PER DISTRIBUTION: 2
FREQUENCY OF DISTRIBUTION: 1
PROGRAMME OF ANALYSIS:
Detection of recurrent abnormalities and/or testing of whole genome copy number changes and structural rearrangements.
Satisfactory/Poor. A non-submission is also given a poor performance.
PERSISTENT POOR PERFORMANCE:
This is defined as: a) Two poor performances in any haematology cytogenetic EQA in which the laboratory participates, over three or more distributions of material, within a 36 month rolling period; b) A poor performance within one year following a previous persistent poor performance designation.
GenQA (Genomics Quality Assessment) provides external quality assessment (EQA) / proficiency testing (PT) to the genomics community worldwide. GenQA EQAs cover the entire clinical genomics service from patient counselling, sample preparation, testing processes, results interpretation and reporting. Laboratories and individual clinicians have access to more than 100 unique EQAs available for a range of rare and inherited disorders and acquired diseases. Please click here for an overview of GenQA